

Amendments to the Claims

The listing of claims will replace all prior versions, and listings of claims in the application.

Claims 1-4 (Cancelled).

Claim 5 (Withdrawn). An isolated nucleic acid encoding the polypeptide of SEQ ID NO: 4 (mouse NgR3) or SEQ ID NO: 14 (human NgR3).

Claims 6-30 (Cancelled).

Claim 31 (New). An isolated polynucleotide comprising a first nucleic acid which encodes a polypeptide at least 80% identical a polypeptide comprising amino acids 1 to 310 of SEQ ID NO:2, wherein said polypeptide modulates inhibition of axonal elongation.

Claim 32 (New). The polynucleotide of claim 31, wherein said polypeptide is at least 90% identical to amino acids 1 to 310 of SEQ ID NO:2.

Claim 33 (New). The polynucleotide of claim 32, wherein said polypeptide is at least 95% identical to amino acids 1 to 310 of SEQ ID NO:2.

Claim 34 (New). The polynucleotide of claim 33 wherein said polypeptide comprises amino acids 1 to 310 of SEQ ID NO:2.

Claim 35 (New). The polynucleotide of claim 31, further comprising a second nucleic acid.

Claim 36 (New). The polynucleotide of claim 35, wherein said second nucleic acid encodes a heterologous polypeptide.

Claim 37 (New). The polynucleotide of claim 36, wherein said heterologous polypeptide forms a fusion protein with the polypeptide encoded by said first nucleic acid.

Claim 38 (New). The polynucleotide of claims 37, wherein said heterologous polypeptide is Fc.

Claim 39 (New). The polynucleotide of claim 37, wherein said heterologous polypeptide is selected from the group consisting of Glutathione S-transferase (GST), a Histidine tag (His tag), and alkaline phosphatase (AP).

Claim 40 (New). A vector comprising the polynucleotide of claim 31.

Claim 41 (New). The vector of claim 40, wherein said polynucleotide is operably linked to one or more expression control elements.

Claim 42 (New). A host cell comprising the polynucleotide of claim 31.

Claim 43 (New). The host cell of claim 42, wherein said polynucleotide is operably linked to one or more expression control elements.

Claim 44 (New). An isolated polynucleotide comprising a first nucleic acid which encodes a polypeptide at least 80% identical to a polypeptide comprising amino acids 31 to 310 of SEQ ID NO:2, wherein said polypeptide modulates inhibition of axonal elongation.

Claim 45 (New). The polynucleotide of claim 44, wherein said polypeptide is at least 90% identical to amino acids 31 to 310 of SEQ ID NO:2.

Claim 46 (New). The polynucleotide of claim 45, wherein said polypeptide is at least 95% identical to amino acids 31 to 310 of SEQ ID NO:2.

Claim 47 (New). The polynucleotide of claim 46, wherein said polypeptide comprises amino acids 31 to 310 of SEQ ID NO:2.

Claim 48 (New). The polynucleotide of claim 44, further comprising a second nucleic acid.

Claim 49 (New). The polynucleotide of claim 48, wherein said second nucleic acid encodes a heterologous polypeptide.

Claim 50 (New). The polynucleotide of claim 49, wherein said heterologous polypeptide forms a fusion protein with the polypeptide encoded by said first nucleic acid.

Claim 51 (New). The polynucleotide of claims 50, wherein said heterologous polypeptide is Fc.

Claim 52 (New). The polynucleotide of claim 50, wherein said heterologous polypeptide is selected from the group consisting of Glutathione S-transferase (GST), a Histidine tag (His tag), and alkaline phosphatase (AP).

Claim 53 (New). A vector comprising the polynucleotide of claim 44.

Claim 54 (New). The vector of claim 53, wherein said polynucleotide is operably linked to one or more expression control elements.

Claim 55 (New). A host cell comprising the polynucleotide of claim 44.

Claim 56 (New). The host cell of claim 55, wherein said polynucleotide is operably linked to one or more expression control elements.

Claim 57 (New). An isolated polynucleotide comprising a first nucleic acid which encodes, except for 1 to 10 conservative amino acid substitutions, a polypeptide selected from the group consisting of amino acids 1-310 of SEQ ID NO:2 and amino acids 31-310 of SEQ ID NO:2; wherein said polypeptide modulates inhibition of axonal elongation.

Claim 58 (New). The polynucleotide of claim 57, further comprising a second nucleic acid.

Claim 59 (New). The polynucleotide of claim 58, wherein said second nucleic acid encodes a heterologous polypeptide.

Claim 60 (New). The polynucleotide of claim 59, wherein said heterologous polypeptide forms a fusion protein with the polypeptide encoded by said first nucleic acid.

Claim 61 (New). The polynucleotide of claims 60, wherein said heterologous polypeptide is Fc.

Claim 62 (New). The polynucleotide of claim 60, wherein said heterologous polypeptide is selected from the group consisting of Glutathione S-transferase (GST), a Histidine tag (His tag), and alkaline phosphatase (AP).

Claim 63 (New). A vector comprising the polynucleotide of claim 57.

Claim 64 (New). The vector of claim 63, wherein said polynucleotide is operably linked to one or more expression control elements.

Claim 65 (New). A host cell comprising the polynucleotide of claim 57.

Claim 66 (New). The host cell of claim 65, wherein said polynucleotide is operably linked to one or more expression control elements.